2-chloroadenosine has been researched along with Cancer, Second Primary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Januszewicz, H; Quach, H; Westerman, D | 1 |
| Birtolo, S; Bocchia, M; Forconi, F; Lauria, F; Marotta, G; Raspadori, D; Rondelli, D; Salvucci, M; Tura, S; Ventura, MA; Zinzani, PL | 1 |
| Flandrin, G; Maloisel, F; Troussard, X | 1 |
| Clausen, NT; Hansen, PB; Larsen, CR | 1 |
1 review(s) available for 2-chloroadenosine and Cancer, Second Primary
| Article | Year |
|---|---|
Hairy cell leukemia. What is new forty years after the first description?
Topics: 2-Chloroadenosine; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; B-Lymphocytes; Bone Marrow; Clinical Trials as Topic; Deoxyadenosines; Humans; Immunologic Factors; Interferon Type I; Leukemia, Hairy Cell; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Proteins; Splenectomy; Vidarabine | 1998 |
1 trial(s) available for 2-chloroadenosine and Cancer, Second Primary
| Article | Year |
|---|---|
Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
Topics: 2-Chloroadenosine; Antimetabolites, Antineoplastic; Bone Marrow; Deoxyadenosines; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Splenomegaly; Survival Rate; Time Factors | 1997 |
2 other study(ies) available for 2-chloroadenosine and Cancer, Second Primary
| Article | Year |
|---|---|
Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
Topics: 2-Chloroadenosine; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Therapy; Cyclophosphamide; Deoxyadenosines; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Neoplasms, Second Primary; Prednisolone; Recurrence; Red-Cell Aplasia, Pure; Remission Induction; Rituximab; Splenectomy; Urinary Bladder Neoplasms | 2005 |
Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
Topics: 2-Chloroadenosine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nucleosides; Vidarabine | 2002 |